FY2025 Earnings Forecast for RCKT Issued By Leerink Partnrs

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) – Investment analysts at Leerink Partnrs increased their FY2025 earnings per share estimates for Rocket Pharmaceuticals in a report released on Monday, November 18th. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will earn ($2.31) per share for the year, up from their previous estimate of ($2.46). The consensus estimate for Rocket Pharmaceuticals’ current full-year earnings is ($2.85) per share.

Other research analysts have also issued research reports about the stock. Needham & Company LLC restated a “buy” rating and set a $52.00 price target on shares of Rocket Pharmaceuticals in a report on Tuesday. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 target price on shares of Rocket Pharmaceuticals in a report on Tuesday. JPMorgan Chase & Co. increased their price target on Rocket Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a report on Tuesday, August 6th. Chardan Capital reissued a “buy” rating and issued a $62.00 price objective on shares of Rocket Pharmaceuticals in a research report on Monday, November 18th. Finally, Scotiabank started coverage on Rocket Pharmaceuticals in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $50.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, Rocket Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $51.00.

Rocket Pharmaceuticals Price Performance

Rocket Pharmaceuticals stock opened at $14.11 on Thursday. The stock’s 50 day moving average is $17.26 and its 200 day moving average is $19.93. Rocket Pharmaceuticals has a one year low of $12.62 and a one year high of $32.53. The firm has a market cap of $1.29 billion, a P/E ratio of -5.14 and a beta of 1.09. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.05 and a quick ratio of 6.05.

Institutional Investors Weigh In On Rocket Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in RCKT. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Rocket Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,292 shares of the biotechnology company’s stock worth $61,000 after acquiring an additional 582 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in Rocket Pharmaceuticals by 31.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,160 shares of the biotechnology company’s stock worth $68,000 after purchasing an additional 764 shares in the last quarter. Values First Advisors Inc. purchased a new stake in shares of Rocket Pharmaceuticals in the third quarter worth approximately $108,000. SG Americas Securities LLC bought a new position in shares of Rocket Pharmaceuticals in the third quarter valued at approximately $113,000. Finally, XTX Topco Ltd purchased a new position in shares of Rocket Pharmaceuticals during the third quarter valued at approximately $286,000. Institutional investors and hedge funds own 98.39% of the company’s stock.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.